Biotech · Private company
Cognitive Research Corporation
Track this companyFree. Adds Cognitive Research Corporation to your Dealase workspace and tells you when its record changes.
Clinical trials181 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials18
- Study of the BIOPIN 6 Naltrexone Implant in Healthy AdultsPHASE1 · COMPLETED · started Jun 24, 2024ClinicalTrials.gov NCT06216132 · fetched Nov 12, 2026
- A Study of ANAVEX3-71 in Adults With SchizophreniaPHASE2 · ACTIVE_NOT_RECRUITING · started Mar 15, 2024ClinicalTrials.gov NCT06245213 · fetched Nov 12, 2026
- Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy VolunteersPHASE1 · COMPLETED · started Apr 11, 2023ClinicalTrials.gov NCT05547503 · fetched Nov 12, 2026
- Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)PHASE3 · TERMINATED · started Dec 5, 2022ClinicalTrials.gov NCT05665088 · fetched Nov 12, 2026
- Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)PHASE3 · COMPLETED · started Apr 27, 2022ClinicalTrials.gov NCT05271552 · fetched Nov 12, 2026
- An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With DementiaPHASE2 · TERMINATED · started Feb 8, 2022ClinicalTrials.gov NCT05276830 · fetched Nov 12, 2026
- Safety and Efficacy of HB-1 for Panic DisorderPHASE2 · COMPLETED · started Feb 3, 2022ClinicalTrials.gov NCT05071430 · fetched Nov 12, 2026
- Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSimPHASE1 · COMPLETED · started Jul 16, 2021ClinicalTrials.gov NCT04970342 · fetched Nov 12, 2026
- Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer PainPHASE2 · UNKNOWN · started May 26, 2021ClinicalTrials.gov NCT03564548 · fetched Nov 12, 2026
- Study of BXCL501 In Agitation Associated With Delirium in ICU PatientsPHASE2 · WITHDRAWN · started Feb 23, 2021ClinicalTrials.gov NCT05313386 · fetched Nov 12, 2026
- Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid WithdrawalPHASE1_PHASE2 · COMPLETED · started Jun 9, 2020ClinicalTrials.gov NCT04470050 · fetched Nov 12, 2026
- Dexmedetomidine in the Treatment of Agitation Associated With Bipolar DisorderPHASE3 · COMPLETED · started Feb 24, 2020ClinicalTrials.gov NCT04276883 · fetched Nov 12, 2026
- Dexmedetomidine in the Treatment of Agitation Associated With SchizophreniaPHASE3 · COMPLETED · started Jan 24, 2020ClinicalTrials.gov NCT04268303 · fetched Nov 12, 2026
- Sub-Lingual Dexmedetomidine in Agitation Associated With DementiaPHASE1_PHASE2 · COMPLETED · started Dec 27, 2019ClinicalTrials.gov NCT04251910 · fetched Nov 12, 2026
- A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With SchizophreniaPHASE2 · COMPLETED · started Nov 26, 2019ClinicalTrials.gov NCT04158687 · fetched Nov 12, 2026
- Sub-Lingual Dexmedetomidine in Agitation Associated With SchizophreniaPHASE1 · COMPLETED · started May 22, 2019ClinicalTrials.gov NCT04010305 · fetched Nov 12, 2026
- Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALSPHASE1 · COMPLETED · started Feb 2, 2018ClinicalTrials.gov NCT03520517 · fetched Nov 12, 2026
- Driving Simulation to Assess Non-Sedative Effects of TolperisonePHASE1 · COMPLETED · started Jul 31, 2017ClinicalTrials.gov NCT03353922 · fetched Nov 12, 2026